IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: "Harnessing γδ T cells through engineering and combination therapies" in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors and hematologic cancers.

γδ T cells differ from conventional alpha-beta T cells through their ability to recognize stress-associated signals independent of major histocompatibility complex (MHC) restriction. This potentially solves problems associated with therapeutic development and enables them to target tumors that evade traditional immune responses. The publication reviews emerging engineering strategies, including CAR-γδ T cells, cytokine-armored γδ T cells, TCE approaches, and antibody-secreting γδ T cells, as well as combination approaches involving checkpoint inhibitors, chemotherapy, cytokines, and bispecific antibodies.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.